- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06766903
Onco-Vascular Exer-Study
Effects of a Physical Exercise Program on Cardiovascular, Metabolic, Physical Fitness and Quality of Life in Cancer Survivors' Adult Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite the "solid" evidence in favor of the effects of exercise training in cancer survivors (CS) to improve variables such as anxiety, depressive symptoms, fatigue, quality of life, lymphedema, and physical function, unfortunately they are still unknown and there is minimal evidence about the effects of exercise training on cardio-vascular and metabolic variables in cancer survivors' persons. The phenomenon of the exercise training in CS persons is of relevance, because as it is pointed out, cancer is the second cause of death in Chile, and in particular breast cancer is the first cause among all types of cancer, and where exercise training has a relevant value as a treatment and post-treatment. Thus, it is required to fill the scientific gap in terms of the need to increase the evidence of exercise training in cardio-vascular physiologyof CS population, such as parameters related to blood pressure, and endothelial dysfunction such as carotid intima-media thickness (cIMT), dilation-mediated flow (FMD) and pulse wave velocity (PWV), as well as metabolic factors related to the resting metabolism and metablism during exercise such as the oxidative and glycolytic capacity, which determine the oxidation of fat and glucose during resting and exercise. There is consolidated or "solid" evidence, about the effects of physical exercise, according to the American College of Sports Medicine (ACSM) exercise recommendations guide for CS.
Different types of exercise training modalities have been reported in breast CS individuals during and following the completion of their treatment (Radiotherapy, Chemotherapy, Hormonal therapy), where the benefits of aerobic nature exercise training predominantly (i.e., exercises that promote an increase in aerobic enzymatic activity, mitochondrial biogenesis and in general oxidative metabolism [that promote the elaboration of ATP via fatty acids]) in combination with muscle strength as resistance training with the use of external overloads (i.e., controlled exercises with a certain level of muscle load based on prior assessment of maximal strength, usually measured by means of 1-repetition maximal test on different muscle groups), which are exercises that promote an increase in protein synthesis, muscle mass formation, and therefore both types of exercise training (Moderate-intensity continuous [MICT] + resistance training [RT]) are usually referred to in the literature as combined exercise or concurrent exercise (MICT+RT). Among the main effects or benefits of exercise training in breast CS individuals, particularly in terms of reducing anxiety, depressive symptoms, fatigue, quality of life, lymphedema, and physical function. It has also been reported that there is only "moderate" evidence on the effects of exercise in CS at the level of bone health, and sleep, but worryingly, there is insufficient evidence in favor of physical exercise at the level of vascular function, falls, cognitive function, and pain, among other health parameters (sexual function, nausea, peripheral neuropathies). The potential results of the project will ultimately translate into greater technical, scientific and management knowledge to be able to analyze the increase in the offer of physical exercise programs or workshops for breast CS persons in Chile. The latter should translate into an improvement not only in the physical condition and health of CS people, but also in a lower risk of relapsing into cancer, mental illnesses (depression) and, of course, a reduction in mortality. From here, high-intensity interval training, a particular exercise modality of brief intense exercise intervals have been poorly studied in breast CS. Similarly, RT using lower exercise intensities (i.e., one repetition maximum test [1RM] load of ≤60% of 1 RM) have been also little tested for cardio-vascular (i.e., PWV, FMD, and cIMT) and metabolic health in breast CS women. Preliminary evidence show that concurrent exercise training decrease blood pressure, and that high-intensity interval training (HIIT) also decrease arterial stiffness in adult women. Eight-weeks of HIIT was superior to MICT for increasing FMD in HIIT vs MICT (Δ+8.9 vs. 5.1%). Twelve-weeks of HIIT (four sets [4 min] intervals at 80-90% HRmax with resting periods of 60-70% HRmax cycling) reduced minimally PWV (-0.1 m·s-1) in hypertensive older adults. One-year of HIIT (60 s interval, 60 s of resting at 90% of the reserve oxygen consumption) decreased both systolic [SBP] (Δ-6.5)/diastolic [DBP] blood pressure (Δ-4.2 mmHg), and decreased cIMTav (Δ-0.95 mm). Thus, concurrent training of both HIIT plus RT in lower 1RM intensities could promote potential benefits for both cardiovascular health and metabolic and physical condition parameters of breast CS women, however, there is scarcity of studies about this exercise modalities in patients who are CS and that have been exposure to higher and lower chemotherapy doses.
RESEARCH PROBLEM: Despite the "solid" evidence in favor of the effects of exercise training in breast CS to improve variables such as anxiety, depressive symptoms, fatigue, quality of life, lymphedema and physical function, however, unfortunately, the effects of exercise training on cardio-vascular and metabolic variables, there is still unknown the effects of concurrent exercise training including HIIT plus RT in lower 1RM doses in CS women at level of their cardio-vascular and metabolic health. This is due to the fact that year after year there is an increase in the number of early diagnoses, as well as an increase in the number of CS with a successful completion of their breast cancer treatment (Radiotherapy, Chemotherapy, Hormonal Therapy), which also leads as an effect to an inherent increase in the number of CS persons, requiring the insertion of this population back into active life. Another effect of the scientific rationale lies in the scarce offer of physical activity and/or exercise training programs for this population of women between 40 and 70 years of age, which would be significantly overcome with the application of the present intervention project that would report cardiovascular, metabolic, physical condition, quality of life and eating patterns variables.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Talcahuano, Chile
- ICER-Lab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Breast cancer diagnosed
- With/without chemotherapy treatment
- Normal weight body mass index [BMI] 18.6 to 24.9 or overweight/obesity condition by BMI 25.0 to 39.9 kg/m2
- Age 30 to 75 years
- With/without other associated co-morbidities (diagnosed of elevated fasting glucose, prediabetes or diabetes, hypertension or prehypertension, or metabolic syndrome, fatty liver or hypercholesterolemia or screened by our research team).
- With/without hormonal therapy
- With/without other pharmacotherapy for specific muscle-groups such as morphine patches, morphine droplets or other pharmacological therapy for SOS pain treatment
Exclusion Criteria:
- History of abnormal ECG
- Diagnosis of other cardio-vascular condition/history other than hypertension, vasculopathy
- History of uncontrolled stage 3 of hypertension or hypertensive crisis
- Diabetes complications such as varicose ulcers, nephropathies
- Skeletal muscle abnormalities (e.g., knee, or hip arthrosis, muscle pain)
- Using weight loss treatment/pharmacotherapy or being active in exercise training programs (or within the past three months)
- Use other pharmacotherapy that can influence body weight loss,
- Respiratory disease type (chronic obstructive disease)
- Kidney disease
- Pregnancy
- Smoking behaviour or dependence on other substances.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: EG-HCT
(EG-HCT) Exercise group high chemotherapy dose: All participants of this groups will be breast cancer survivors and received no more than 7 chemotherapy sessions during cancer treatment.
|
All subjects will participate of 8-weeks of exercise training intervention of concurrent training of high-intensity interval training (HIIT) using stationnaire bikes plus resistance training (RT) using free weight under lab conditions. The exercise program will be monitored by 8-weeks, adapted individually to each participants in terms of exercise intensity an volume.
Other Names:
|
|
Active Comparator: EG-LCT
(EG-LCT) Exercise group low chemotherapy dose: All participants of this groups will be breast cancer survivors and received more than 8 chemotherapy sessions during cancer treatment.
|
All subjects will participate of 8-weeks of exercise training intervention of concurrent training of high-intensity interval training (HIIT) using stationnaire bikes plus resistance training (RT) using free weight under lab conditions. The exercise program will be monitored by 8-weeks, adapted individually to each participants in terms of exercise intensity an volume.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Flow-mediated dilation in (cm)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in flow-mediated dilation in the brachial artery registered by a linear transducer using images from a Doppler ultrasound
|
Baseline, 8 weeks after exercise training intervention
|
|
Pulse wave velocity in (m/s)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in pulse wave velocity in the brachial artery registered by an oscillometric cuff in the brachial artery
|
Baseline, 8 weeks after exercise training intervention
|
|
Carotid intima media thickness average in (cm)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Carotid intima media thickness in the common carotid artery registered by a linear transducer using images from a Doppler ultrasound
|
Baseline, 8 weeks after exercise training intervention
|
|
Carotid intima media thickness maximum in (cm)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Carotid intima media thickness maximum in the common carotid artery registered by a linear transducer using images from a Doppler ultrasound
|
Baseline, 8 weeks after exercise training intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body mass in (kg)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in body mass registered by a digital scale in kilograms
|
Baseline, 8 weeks after exercise training intervention
|
|
Body mass index in (kg/m2)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in body mass index registered by from the calculation of the weight plus the height dividev by the suare of the height
|
Baseline, 8 weeks after exercise training intervention
|
|
Body fat in (%)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in body fat percentage registered by from a digital bio-impedanciometer equipment
|
Baseline, 8 weeks after exercise training intervention
|
|
Skeletal muscle mass in (%)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in skeletal muscle mass in percentage registered by from a digital bio-impedanciometer equipment
|
Baseline, 8 weeks after exercise training intervention
|
|
Resting metbolic rate in (kcal)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in resting metabolic rate obtained in kcalories from a digital bio-impedanciometer equipment
|
Baseline, 8 weeks after exercise training intervention
|
|
Waist circumference in (cm)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in waist circumference obtained from a measuring tape in centimeters
|
Baseline, 8 weeks after exercise training intervention
|
|
Systolic blood pressure in (mmHg)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in systolic blood pressure obtained from a digital cuff sphingomanometer in mmHg from the brachial artery in seated position
|
Baseline, 8 weeks after exercise training intervention
|
|
Diastolic blood pressure in (mmHg)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in diastolic blood pressure obtained from a digital cuff sphingomanometer in mmHg from the brachial artery in seated position
|
Baseline, 8 weeks after exercise training intervention
|
|
Mean arterial pressure in (mmHg)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in mean arterial pressure obtained from a digital cuff sphingomanometer in mmHg from the brachial artery in seated position, particularly from the data systolic and diastolic blood pressure obtained from this equipment
|
Baseline, 8 weeks after exercise training intervention
|
|
Pulse pressure in (mmHg)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in pulse pressure obtained from a digital cuff sphingomanometer in mmHg from the brachial artery in seated position, particularly from the data systolic and diastolic blood pressure obtained from this equipment
|
Baseline, 8 weeks after exercise training intervention
|
|
Heart rate at rest in (beats/min)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in heart rate at rest obtained from a digital watch cardiometer in beats/min
|
Baseline, 8 weeks after exercise training intervention
|
|
Systolic blood pressure of the ankle in (mmHg)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in systolic blood pressure obtained from a digital cuff sphingomanometer in mmHg by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Diastolic blood pressure of the ankle in (mmHg)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in systolic blood pressure obtained from a digital cuff sphingomanometer in mmHg by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Partial oxygen saturation in (%)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Partial oxygen saturation in (%) obtained from a digital saturometer from the index finger in seated position
|
Baseline, 8 weeks after exercise training intervention
|
|
Total chlesterol in (mg/dL)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in total cholesterol in (mg/dL) obtained from a capillary droplet sample from the index finger from a digital portatile equipment
|
Baseline, 8 weeks after exercise training intervention
|
|
Fasting glucose in (mg/dL)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in fasting glucose in (mg/dL) obtained from a capillary droplet sample from the index finger from a digital portatile equipment
|
Baseline, 8 weeks after exercise training intervention
|
|
Triglycerides in (mg/dL)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in triglycerides in (mg/dL) obtained from a capillary droplet sample from the index finger from a digital portatile equipment
|
Baseline, 8 weeks after exercise training intervention
|
|
Lactate
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Lactate in (mmol/L) obtained from a capillary droplet sample from the index finger from a digital portatile equipment
|
Baseline, 8 weeks after exercise training intervention
|
|
Augmentation index in (%)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Augmentation index in (%) obtained from a digital cuff sphingomanometer in mmHg by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Ankle-Brachial Index in (%)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Ankle-Brachial Index in (%) obtained from a digital cuff sphingomanometer in mmHg by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Aortic Systolic blood pressure in (mmHg)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Aortic Systolic blood pressure in (mmHg) obtained from a digital cuff sphingomanometer in mmHg by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Aortic pulse pressure in (mmHg)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Aortic pulse pressure in (mmHg) obtained from a digital cuff sphingomanometer in mmHg by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Aortic augmentation index in (%)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Aortic augmentation index in (%) obtained from a digital cuff sphingomanometer in % by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Ejection duration in (m/s)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Ejection duration in (m/s) obtained from a digital cuff sphingomanometer in % by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Diastolic reflection area
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Diastolic reflection area obtained from a digital cuff sphingomanometer in % by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Systolic area index
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Diastolic area index obtained from a digital cuff sphingomanometer in % by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Diastolic area index
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Diastolic area index obtained from a digital cuff sphingomanometer in % by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Return time of the aortic pulse wave
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in Return time of the aortic pulse wave measured in the brachial artery obtained from a digital cuff sphingomanometer in % by the Arteriograpgh equipment from the brachial artery in supine position.
|
Baseline, 8 weeks after exercise training intervention
|
|
Arterial age
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in arterial age estimated from a digital cuff Arteriograph equipment measured from the brachial artery
|
Baseline, 8 weeks after exercise training intervention
|
|
Heart rate during exercise in (beats/min)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Heart rate measured using a cardiometer watch equipment at different power output intensities using an cycle ergometer equipment
|
Baseline, 8 weeks after exercise training intervention
|
|
Peak oxigen consumption (VO2peak)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in VO2peak estimated from an equipment of indirect calorimetry and gas calibration of O2/VCO2, measured from breathing by breathing on a stationnaire bike ergometer
|
Baseline, 8 weeks after exercise training intervention
|
|
Fat oxidation (FATox)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in FATox estimated from an equipment of indirect calorimetry and gas calibration of O2/VCO2, measured from breathing by breathing during 10 minutes on a stretcher
|
Baseline, 8 weeks after exercise training intervention
|
|
Carbohydrate oxidation (CHOox)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in CHOox estimated from an equipment of indirect calorimetry and gas calibration of O2/VCO2, measured from breathing by breathing during 10 minutes on a stretcher
|
Baseline, 8 weeks after exercise training intervention
|
|
Maximum strength of leg extension (1RMleg)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in the 1RMleg strength estimated from a leg-extension exercise machine using kilograms
|
Baseline, 8 weeks after exercise training intervention
|
|
Maximum strength of biceps curl (1RMbiceps)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in the 1RMbiceps strength estimated using free weight in kilograms, bilateral and in stand position
|
Baseline, 8 weeks after exercise training intervention
|
|
Maximum strength of shoulder press (1RMsp)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in the 1RMsp strength estimated using free weight in kilograms, bilateral and in stand position
|
Baseline, 8 weeks after exercise training intervention
|
|
Maximum strength of back exercise (1RMb)
Time Frame: Baseline, 8 weeks after exercise training intervention
|
Change in the 1RMb strength estimated using free weight in kilograms, bilateral and in stand position
|
Baseline, 8 weeks after exercise training intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Rodrigo Araneda, PhD, Universidad Andrés Bello
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UNAB-FCR-KINE2024A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Exercise training
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
University of British ColumbiaMichael Smith Foundation for Health ResearchCompleted
-
Universidade Norte do ParanáCompleted
-
Universita di VeronaRecruiting
-
University of Colorado, DenverVA Eastern Colorado Health Care SystemCompletedHealthy | Overweight | Type 2 Diabetes Mellitus | Cardiovascular Risk FactorUnited States
-
National Taiwan University HospitalCompletedAtrial FibrillationTaiwan
-
Hacettepe UniversityCompleted
-
University of LeipzigCompletedImpact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CADStable Coronary Artery DiseaseGermany
-
Helse Stavanger HFStavanger Health ResearchCompletedVentricular TachycardiaNorway
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada